Read + Share
Katz DA, Morris JD, Chu MP, David KA, et al. Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in
adults with newly diagnosed, high-risk DLBCL. Leuk Lymphoma 2022;63:2063-2073.
PMID: 35503708
|
 |
|
Katz DA, Morris JD, Chu MP, David KA, et al. Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in
adults with newly diagnosed, high-risk DLBCL. Leuk Lymphoma 2022;63:2063-2073.
PMID: 35503708
|
|
|
|